NKTR
NEKTAR THERAPEUTICS
NASDAQ · Healthcare · Biotechnology · US
$36.64
+2.40%Oct 1, 2026, 15:45 UTC
Nektar Therapeutics reported sustained hair regrowth after treatment ended in its hair loss treatment data.
Source:Sep 30, 2026, 14:30 UTC
Nektar Therapeutics and collaborators at the Icahn School of Medicine at Mount Sinai presented new multi-omic biomarker sub-study results from REZOLVE-AD at the EADV Congress 2026, showing early molecular responses to rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis.
Source:Sep 28, 2026, 12:00 UTC
Nektar Therapeutics announced that data from its Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata will be presented in three oral presentations at the EADV Congress 2026 in Vienna, Austria, and will host an investor conference call on October 1, 2026.
Source:Sep 25, 2026, 11:03 UTC
A jury awarded Nektar Therapeutics $90 million plus interest in its case against Eli Lilly.
Source:Aug 25, 2026, 12:30 UTC
Nektar Therapeutics announced the publication in The Lancet of positive Phase 2b REZOLVE-AD 16-week induction results for rezpegaldesleukin in moderate-to-severe atopic dermatitis, meeting all primary and key secondary endpoints.
Source:Aug 14, 2026, 02:04 UTC
Nektar Therapeutics finalized plans for a registrational Phase III trial in alopecia areata following an end-of-Phase II meeting with the U.S. Food and Drug Administration.
Source:Aug 14, 2026, 02:04 UTC
Nektar Therapeutics initiated its global Phase III ZENITH AD program for rezpegaldesleukin in moderate-to-severe atopic dermatitis during July 2026.
Source:Aug 11, 2026, 11:50 UTC
Kuehn Law, PLLC announced it is investigating potential breaches of fiduciary duty by officers and directors of Nektar Therapeutics, based on a federal securities lawsuit alleging misrepresentations about the REZOLVE-AA trial.
Source:Aug 11, 2026, 05:26 UTC
Nektar Therapeutics will release its Q2 2026 earnings after market close on Thursday, August 13th.
Jul 21, 2026, 11:00 UTC
Nektar Therapeutics initiated the first two global registrational Phase 3 trials (ZENITH AD-1 and ZENITH AD-2) in the ZENITH AD program for rezpegaldesleukin in moderate-to-severe atopic dermatitis.
Source: